SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

PCSA is trending due to a recent Phase 2 clinical update, leading to significant price volatility and trading halts. The community is actively debating the potential for a short squeeze and comparing it to similar stocks that have experienced rapid gains. Some traders are expressing frustration with trading restrictions and speculating on upcoming catalysts, while others highlight the company's potential in the cancer treatment space.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is trending following the announcement of an AI infrastructure partnership with Anthropic and Fluidstack, including a significant data center lease agreement. The community is discussing the implications of Google's involvement and the potential for Hut 8 to transition from Bitcoin mining to AI infrastructure. Momentum and the shift towards AI infrastructure revenue are key talking points.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave (CRWV) is trending downwards as investors express concerns about its debt, delayed data center construction, and increased competition despite significant contracts with major AI players. The community is debating whether the stock is oversold, with some seeing a buying opportunity while others are wary of insider selling and broader AI sector volatility. Discussions also include the potential impact of macroeconomic factors and competitor performance on CRWV's future.

B. Riley Financial, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

B. Riley Financial Inc

B. Riley Financial ($RILY) is trending due to recent debt restructuring and a swing towards positive EPS, sparking community discussion about a potential turnaround. Bullish investors are drawing parallels to $CVNA's past trajectory, while others focus on high short interest and gamma squeeze potential. However, some traders remain skeptical, citing concerns about debt and fundamental value.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

Galectin Therapeutics ($GALT) is trending amid ongoing discussions about potential FDA guidance on its lead drug candidate, with community members anticipating a positive outcome soon. An analyst upgrade to Buy with a price target of $11 has fueled optimism, while some traders discuss potential short squeezes and upcoming company news. The stock's movement is also attributed to its position within the broader biotech sector and speculation around a potential buyout or partnership.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid reports that the White House may be moving forward with cannabis rescheduling, potentially as early as this week, which could lead to significant tax benefits and increased institutional investment. The community is actively discussing the potential impact of rescheduling on U.S. cannabis companies and speculating on the timing of an official announcement. Many believe rescheduling could catalyze a major rerating for U.S.-based MSOs, while others caution about premature hype and potential profit-taking.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the stock approaches all-time highs, fueled by optimism surrounding its robotaxi program and AI advancements, though regulatory scrutiny in California is a concern. Community discussions are focused on the potential for a continued rally toward the \$500 level, with some debating the stock's valuation amid mixed sentiment.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to a Financial Times report stating Blue Owl Capital will not back a planned data center, triggering concerns about Oracle's AI spending and debt. The community is debating the validity of the report, discussing potential impacts on Oracle's AI initiatives, and assessing whether the stock is oversold or set for a rebound. Some traders are also pointing to a possible coordinated attack.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as the community discusses its potential for a short squeeze and a possible buyout, with some expressing frustration over the current stock price despite a robust pipeline and strong cash position. Some are pointing to biotech sector rotation and potential catalysts from its pipeline. There is chatter regarding a potential partnership or acquisition.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending amid analyst ratings updates and community discussions around price targets, with some traders expressing frustration over recent price action despite the company's growth. Bullish investors emphasize the long-term potential with Alani Nu integration and Pepsi distribution, while others point to potential near-term disruptions and the impact of insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an...

12,916,663 Shares in Vir Biotechnology, Inc. $VIR Bought by ARCH Venture Management LLC

ARCH Venture Management LLC purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the 2nd quarter, according to the company in its most recent filing with...

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Should You Buy?

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up - Still a Buy...

Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of the business's stock in a transaction that occurred on Monday, December 1st...

Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 191,854 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 191,854 shares of the firm's stock in a transaction on Monday, December 1st. The shares were...

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven analysts that are currently covering the stock, MarketBeat.com reports. One...

Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Monday, December 1st. The shares were sold...

Vir Biotechnology (NASDAQ:VIR) Shares Down 7.1% - What's Next?

Vir Biotechnology (NASDAQ:VIR) Trading Down 7.1% - Here's Why...

Ensign Peak Advisors Inc Increases Position in Vir Biotechnology, Inc. $VIR

Ensign Peak Advisors Inc boosted its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 812.7% during the second quarter, according to the company in its most recent Form 13F filing...

Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 235,971 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 235,971 shares of the business's stock in a transaction that occurred on Tuesday, November...

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Current Price	$6.27
Prev Close	$6.48
Open	$6.51
Dividend Yield	0.00%
50-Day Moving Average	$5.97
Beta	1.52
Avg. Volume	1.5M
PE Ratio	-1.79

52-Week High	$14.45
52-Week Low	$4.16
Market Capitalization	$901.53M
EPS (Annual)	-$3.83
Price to Book	1.13
Revenue Per Employee	$181,875.00
Enterprise Value/EBITDA	N/A

VIR
Vir Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VIR News

VIRVir Biotechnology Inc